BRIEF published on 12/22/2025 at 07:05, 10 months 7 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
BRIEF published on 12/22/2025 at 07:05, 10 months 7 days ago GenSight Biologics obtient une autorisation d'usage compassionnel pour GS010/LUMEVOQ® en France Thérapie Génique Maladies Rares Usage Compassionnel Traitement De La LHON Approbation ANSM
BRIEF published on 12/22/2025 at 07:05, 10 months 7 days ago Délivrance d'une autorisation d'accès compassionnel pour GS010/LUMEVOQ® Thérapie Génique GenSight Biologics NOHL Accès Compassionnel ANSM
PRESS RELEASE published on 12/22/2025 at 07:00, 10 months 7 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
PRESS RELEASE published on 12/22/2025 at 07:00, 10 months 7 days ago Informations privilégiées / Autres communiqués GenSight Biologics obtient une autorisation d'accès compassionnel en France pour GS010/LUMEVOQ dans le traitement de la NOHL liée à la mutation ND4 Thérapie Génique GenSight Biologics NOHL GS010/LUMEVOQ Autorisation D'accès Compassionnel
BRIEF published on 11/13/2025 at 18:02, 11 months 15 days ago Franchissement de seuils par Heights Capital Management Obligations Convertibles Franchissement De Seuils GenSight Biologics Actions Et Droits De Vote Heights Capital
BRIEF published on 11/13/2025 at 18:02, 11 months 15 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
PRESS RELEASE published on 11/13/2025 at 17:57, 11 months 15 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils GENSIGHT BIOLOGICS SA Heights Capital Management CVI Investments Inc.
BRIEF published on 10/30/2025 at 07:35, 11 months 29 days ago GenSight Biologics : Feu vert pour un traitement compassionnel aux États-Unis FDA GenSight Biologics NOHL Accès Compassionnel GS010/LUMEVOQ®
BRIEF published on 10/30/2025 at 07:35, 11 months 29 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
Published on 10/29/2026 at 07:30, 2 minutes ago Tocvan Pilot Mine Trench at Gran Pilar Averages 4.6 g/t Au With Samples Up to 24.4 g/t Au; New Zone 1.3 km East Returns Up to 234 g/t Ag
Published on 10/28/2026 at 22:35, 8 hours 57 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 19 hours 2 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 19 hours 2 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 19 hours 2 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/29/2026 at 07:15, 17 minutes ago AMAG Austria Metall AG: Strong earnings growth in the first three quarters of 2026
Published on 10/29/2026 at 07:05, 27 minutes ago Familiar, uncanny, urban Two new exhibitions in the Helvetia Art Foyer and the Baloise Park Art Forum
Published on 10/29/2026 at 07:05, 27 minutes ago Familier, étranger, urbain Deux nouvelles expositions au Foyer d'art Helvetia et au Forum des arts du Baloise Park
Published on 10/29/2026 at 07:00, 31 minutes ago Implenia bénéficie du marché pour la construction d’un nouveau bâtiment des hôpitaux de Schaffhouse
Published on 10/29/2026 at 07:00, 31 minutes ago Implenia wins contract for the construction of the new Schaffhausen hospital
Published on 10/29/2026 at 07:20, 12 minutes ago Q3 2026: Air Liquide accelerates, driven by sales growth and the launch of its strategic plan
Published on 10/29/2026 at 07:20, 12 minutes ago T3 2026 : Air Liquide accélère, porté par des ventes en croissance et le lancement de son plan stratégique
